Department of Orthopedics, Taizhou Municipal Hospital, Taizhou, Zhejiang, China.
Department of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China.
Front Endocrinol (Lausanne). 2023 Jul 4;14:1180183. doi: 10.3389/fendo.2023.1180183. eCollection 2023.
Nephrolithiasis is thought to be a risk factor for osteoporosis, but data assessing if osteoporosis predisposes to the risk of nephrolithiasis are lacking. The present study aims to investigate whether patients with nephrolithiasis have a prominently higher prevalence of osteoporosis than the controls and via a cumulative analysis.
Four databases were used to detect the eligible studies. We calculated the relative risk (RR) with a 95% confidence interval (CI) to assess the combined effect. The methodologies for conducting this study followed the PRISMA guidelines and were registered in the PROSPERO (ID: CRD42023395875).
Nine case-control or cohort studies with a total of 454,464 participants were finally included. Combined results indicated that there was a significantly higher prevalence of osteoporosis in patients with nephrolithiasis as compared to the general population without nephrolithiasis (overall RR from six studies= 1.204, 95%CI: 1.133 to 1.28, < 0.001; heterogeneity: 34.8%, = 0.162). Conversely, osteoporosis was significantly correlated to an increased risk of nephrolithiasis as compared to the controls without osteoporosis (overall RR from four studies= 1.505, 95%CI: 1.309 to 1.731, < 0.001; 89.8%, < 0.001). Sensitivity analysis on the two categories validated the above findings. No significant publication bias was identified in this study.
The present study highlighted a significantly high prevalence of osteoporosis in patients with nephrolithiasis and . This reciprocal association reminded the clinicians to conduct a regular follow-up assessment when managing patients with nephrolithiasis or osteoporosis, especially for the elderly.
https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42023395875.
肾结石被认为是骨质疏松症的一个危险因素，但缺乏评估骨质疏松症是否会增加肾结石风险的数据。本研究旨在通过累积分析，调查肾结石患者的骨质疏松症患病率是否明显高于对照组。
使用四个数据库来检测符合条件的研究。我们计算了相对风险（RR）及其 95%置信区间（CI）来评估合并效应。本研究的方法遵循 PRISMA 指南，并在 PROSPERO（ID：CRD42023395875）中进行了注册。
最终纳入了 9 项病例对照或队列研究，共 454464 名参与者。综合结果表明，肾结石患者的骨质疏松症患病率明显高于无肾结石的普通人群（来自 6 项研究的总体 RR=1.204，95%CI：1.133 至 1.28，<0.001；异质性：34.8%，=0.162）。相反，与无骨质疏松症的对照组相比，骨质疏松症与肾结石风险增加显著相关（来自 4 项研究的总体 RR=1.505，95%CI：1.309 至 1.731，<0.001；89.8%，<0.001）。对这两个类别进行敏感性分析验证了上述发现。本研究未发现明显的发表偏倚。
本研究强调了肾结石患者中骨质疏松症患病率明显升高，且这种相关性提示临床医生在管理肾结石或骨质疏松症患者时，特别是老年人，应进行定期随访评估。
https://www.crd.york.ac.uk/PROSPERO/#searchadvanced，标识符 CRD42023395875。
